Instrument Inactif

Communiqués Alexion Pharmaceuticals, Inc.

Actions

ALXN

US0153511094

Produits pharmaceutiques

Communiqués

17/05/23	AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023	AQ
08/05/23	Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas	AQ
11/11/22	AstraZeneca expands global footprint in rare disease with availability of first Alexion rare disease therapy for patients in China	AQ
28/09/22	Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type 1	AQ
28/09/22	Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type1	AQ
26/09/22	Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gravis	AQ
16/09/22	Danicopan (ALXN2040) add-on to Ultomiris or Soliris met primary endpoint in ALPHA Phase III trial for patients with paroxysmal	AQ
26/08/22	Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis	AQ
25/08/22	Astrazeneca - Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis	AQ
10/06/22	AstraZeneca demonstrates pipeline and portfolio strength across malignant and rare haematological diseases at EHA 2022	AQ
05/05/22	Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder	AQ
28/04/22	Ultomiris approved in the US for adults with generalised myasthenia gravis	AQ
26/04/22	Breaking PMPRB News: Another Win For Patients And The Innovative Pharmaceutical Industry	AQ
12/04/22	PMPRB Update: PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing	AQ
31/03/22	SCC Leave Denied In Alexion Pharmaceuticals Inc v Canada (Attorney General)	AQ
29/03/22	PMPRB Update: Supreme Court Refuses To Hear Appeal From Decision Restricting Canada's Patented Medicine Pricing Review Board's Drug Price Mandate	AQ
01/03/22	AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement to develop and commercialise NI006	AQ
25/01/22	The 2022 PMPRB Outlook For Pharmaceutical Patentees In Canada	AQ
10/01/22	AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006	AQ
07/01/22	AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006	AQ
07/12/21	M&A market remains strong despite decline in activity	AQ
04/12/21	Life Sciences: Vavilov And The New Regulatory Environment	AQ
11/10/21	Alexion Pharmaceuticals : Canada Seeks Leave To Appeal To The Supreme Court In PMPRB Excessive-pricing Case	AQ
28/08/21	Alexion Pharmaceuticals : FCA Remits Pricing Decision On ALEXION'S SOLIRIS To PMPRB	AQ
23/08/21	Alexion Pharmaceuticals : Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotrophic lateral sclerosis	AQ